Frequency of common CYP1B1 polymorphic variations in Delhi population of Northern India

Environmental Toxicology and Pharmacology

Volumn 28, Issue 3, 2009, Pages 392-396

  Kumar, Vivek ^a   Singh, Satyender ^b   Ahmed, Rafat Sultana ^a   Banerjee, Basu Dev ^a   Ahmed, Tanzeel ^a   Pasha, Syed Tazeen ^b  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^b NATIONAL INSTITUTE OF COMMUNICABLE DISEASES   (India)

Author keywords

Cancer; Cytochrome P450; Estrogen; Polymorphism; Toxins; Xenobiotics

Indexed keywords

ALANINE; ARGININE; CYTOCHROME P450 1B1; GLYCINE; SERINE;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; INDIA; MALE; POPULATION GENETICS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 70349561349     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2009.06.006     Document Type: Article

References (37)

1. Acharya M., Mookherjee S., Bhattacharjee A., Bandyopadhyay A.K., Thakur S.K.D., Bhaduri G., Sen A., and Ray K. Primary role of CYP1B1 in Indian juvenile-onset POAG patients. Mol. Vision 12 (2006) 399-404
2. Aklillu E., Oscarson M., Hidestrand M., Liedvik B., Otter C., and Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol. Pharmacol. 61 (2002) 586-594
3. Bhattacharjee A., Banerjee D., Mookherjee S., Acharya M., Banerjee A., Ray A., Sen A., The Indian Genome Variation Consortium, and Ray K. Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma. Mol. Vision 14 (2008) 841-850
4. Bosland M.C. The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. Monogr. 27 (2000) 39-66
5. Buters J.T., Sakai S., Richter T., Pineau T., Alexander D.L., Savas U., Doehmer J., Ward J.M., Jefcoate C.R., and Gonzalez F.J. Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 1977-1982
6. Caporaso N., and Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 5 (1995) 59-63
7. Doherty J.A., Weiss N.S., Freeman R.J., Dightman D.A., Thornton P.J., Houck J.R., Voigt L.F., Rossing M.A., Schwartz S.M., and Chen C. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 357-366
8. Fukatsu T., Hirokawa Y., Araki T., Hioki T., Murata T., Suzuki H., Ichikawa T., Tsukino H., Qiu D., Katoh T., Sugimura Y., Yatani R., Shiraishi T., and Watanabe M. Genetic polymorphisms of hormone related-genes and prostate cancer risk in the Japanese population. Anticancer Res. 24 (2004) 2431-2437
9. Gong G., Kosoko-Lasaki O., Haynatzki G.R., and Wilson M.R. Genetic dissection of myocilin glaucoma. Hum. Mol. Genet. 13 Spec No 1 (2004) R91-102 (Erratum in: Hum. Mol. Genet. 13, 1991)
10. Goodman M.T., McDuffie K., Kolonel L.N., Terada K., Donlon T.A., Wilkens L.R., Guo C., and Le Marchand L. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol. Biomarkers Prev. 10 (2001) 209-216
11. Hanna I.H., Dawling S., Roodi N., Guengerich F.P., and Parl F.F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 60 (2000) 3440-3444
12. Hayes C.L., Spink D.C., Spink B.C., Cao J.Q., Walker N.J., and Sutter T.R. 17-beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9776-9781
13. Hecht S.S. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol. 3 (2002) 461-469
14. Inoue K., Asao T., and Shimada T. Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica 30 (2000) 285-295
15. Kumar A., Basavaraj M.G., Gupta S.K., Qamar I., Ali A.M., Bajaj V., Ramesh T.K., Prakash D.R., Shetty J.S., and Dorairaj S.K. Role of CYP1B1, MYOC, OPTN and OPTC genes in adult-onset primary open-angle glaucoma: predominance of CYP1B1 mutations in Indian patients. Mol. Vision 13 (2007) 667-676
16. Liehr J.G., and Ricci M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 3294-3296
17. Listgarten J., Damaraju S., Poulin B., Cook L., Dufour J., Driga A., Mackey J., Wishart D., Greiner R., and Zanke B. Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin. Cancer Res. 10 (2004) 2725-2737
18. Nebert D.W., Ingelman-Sundberg M., and Daly A.K. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab. Rev. 31 (1999) 467-487
19. Nebert D.W., Dalton T.P., Okey A.B., and Gonzalez F.J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 279 (2004) 23847-23850
20. Quigley H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80 (1996) 389-393
21. Rochat B., Morsman J.M., Murray G.I., Figg W.D., and McLeod H.L. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?. J. Pharmacol. Exp. Ther. 296 (2001) 537-541
22. Roland J., and Breton L. Atlas of the Languages and Ethnic Communities of South Asia (1993), Saga publication, New Delhi pp. 21-39
23. Roos P.H., and Bolt H.M. Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin. Drug Metab. Toxicol. 1 (2005) 187-202
24. Sasaki M., Tanaka Y., Kaneuchi M., Sakuragi N., and Dahiya R. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor α and estrogen receptor β expressions. Cancer Res. 63 (2003) 3913-3918
25. Sharma M., Shubert D.E., Sharma M., Lewis J., McGarrigle B.P., Bofinger D.P., and Olson J.R. Biotransformation of tamoxifen in a human endometrial explant culture model. Chem. Biol. Interact. 146 (2003) 237-249
26. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., and Sutter T.R. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. 56 (1996) 2979-2984
27. Singh A.P., Shah P.P., Mathur N., Buters J.T., Pant M.C., and Parmar D. Genetic polymorphisms in cytochrome P4501B1 and susceptibility to head and neck cancer. Mutat. Res. 639 (2008) 11-19
28. Singh S., Kumar V., Thakur S., Banerjee B.D., Grover S.S., Rawat D.S., Pasha S.T., Jain S.K., Lal S., and Rai A. Genetic polymorphism of glutathione S-transferase M1 and T1 in Delhi population of Northern India. Environ. Toxicol. Pharmacol. 28 (2009) 25-29
29. Sobti R.C., Onsory K., Al-Badran A.I., Kaur P., Watanabe M., Krishan A., and Mohan H. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol. 25 (2006) 287-294
30. Stoilov I., Akarsu A.N., and Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2P21. Hum. Mol. Genet. 6 (1997) 641-647
31. Stoilov I., Akarsu A.N., Alozie I., Child A., Barsoum-Homsy M., Turacli M.E., Or M., Lewis R.A., Ozdemir N., Brice G., Aktan S.G., Chevrette L., Coca-Prados M., and Sarfarazi M. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet. 62 (1998) 573-584
32. Sutter T.R., Tang Y.M., Hayes C.L., Wo Y.Y., Jabs E.W., Li X., Yin H., Cody C.W., and Greenlee W.F. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. 269 (1994) 13092-13099
33. Tanaka Y., Sasaki M., Kaneuchi M., Shiina H., Igawa M., and Dahiya R. Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem. Biophys. Res. Commun. 296 (2002) 820-826
34. Tang Y.M., Wo Y.Y., Stewart J., Hawkins A.L., Griffin C.A., Sutter T.R., and Greenlee W.F. Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J. Biol. Chem. 271 (1996) 28324-28330
35. Tang Y.M., Green B.L., Chen G.F., Thompson P.A., Lang N.P., Shinde A., Lin D.X., Tan W., Lyn-Cook B.D., Hammons G.J., and Kablubar F.F. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10 (2000) 761-766
36. Wenzlaff A.S., Cote M.L., Bock C.H., Land S.J., Santer S.K., Schwartz D.R., and Schwartz A.G. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 26 (2005) 2207-2212
37. Zheng W., Xie D.W., Jin F., Cheng J.R., Dai Q., Wen W.Q., Shu X.O., and Gao Y.T. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 147-150